Biotech | March 11, 2026
Cirena licenses breakthrough RNA synthesis technology from CU Boulder
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Subscribe To Our Newsletter & Stay Updated
